Latest News
Preservative-Free Is Not Risk-Free: The Microbiology Behind Safe Cosmetics
I have noticed that many shoppers want cosmetics without preservatives, so brands have launched preservative-free cosmetics and other “free-from” lines. The science of microbiology however stays the same. Any product that holds water and nutrients can feed microbes....
Latest News
ZW209 Licensing Deal: What Does Roche Get From Zymeworks?
Under the ZW209 licensing deal with Zymeworks, Roche will receive exclusive global rights to develop and commercialise ZW209. In return, Zymeworks is due $55 million upfront and $40 million when a Phase 1b trial begins. It is also eligible for up to $718 million in...
What FDA’s “Healthy” Rule and Front-of-Pack Labelling Mean for Food Makers
Two changes are reshaping what goes on the front of a US food package. The first, a new definition of the "healthy" nutrient content claim, is already law, with enforcement starting on 25 February 2028 [1]. The second, mandatory front-of-pack labelling in the form of...
Life Science Publishing: Our First Year, and Where You Fit In
Almost a year ago, Life Science Daily News published its first articles with a simple belief. Specialist science deserves a specialist stage. Since then, that belief has grown into a global readership and an active community of contributors. This is the story of our...
Imdelltra Imfinzi Approval: When Could First-Line Use Begin?
Amgen and AstraZeneca presented full DeLLphi-305 results at the ESMO Congress in Madrid. The phase 3 trial added Amgen’s Imdelltra (tarlatamab-dlle) to AstraZeneca’s Imfinzi (durvalumab). It cut the risk of death by 58 per cent in extensive-stage small cell lung...
Join The Future Of Life Sciences Media
In a world overflowing with information, LifeScienceDaily.news stands apart as the dedicated space where life sciences professionals share what’s new, what’s next, and why it matters, all in real time.
Don’t wait for the media to pick up your story. Be the media.
Trending
More News
How AI Is Redefining the Modern Healthcare Consultation
Healthcare in the United States is facing a structural inflection point. Physician burnout remains high. Administrative burdens consume hours that should be spent with patients. Chronic disease rates continue to rise. At the same time, health systems are under...
I’m a Black Gestational Carrier. How People Calculate My Risk Is Wrong
Adding Black maternal-health statistics to data on gestational carriers and calling the sum mine doesn't make it so. The numbers don’t work that way. I’ve carried three pregnancies for other families. I’m also a Black woman. Put those facts beside two well-documented...
Disease Progression Slowing Holds on Function, Misses on Composite
uniQure released four-year results for its Huntington’s disease gene therapy on Tuesday 29 September 2026. The disease progression slowing measured on the composite clinical scale narrowed at 48 months. It missed statistical significance. A second measure, Total...
The Writing Got Cheap. The Checking Did Not
Last month I published a cost analysis with wrong numbers in it. Not rounded wrong. I had taken the wrong price list and the wrong tariff for cache writes, and when I recomputed, the headline figure moved. I issued a corrected version and stopped citing the first one....
The Financial Infrastructure Behind Healthcare Innovation
Healthcare is changing faster than I have ever seen it change, and the revenue cycle has to keep pace. We are talking about AI, new treatments, new technology, new specialties and entirely new ways of delivering care. All of that is exciting, and much of it has the...
Why Complement Therapeutic Research Requires More Than a Single Assay
Complement-targeted drug development requires more than measuring individual proteins. Integrating functional hemolysis assays, carefully selected serum or plasma samples, and multiplex biomarker analysis can provide a more reliable picture of complement activity,...
AstraZeneca Strategic Equity Investment Puts $2bn Into Summit Therapeutics
AstraZeneca has made a 2 billion US dollar strategic equity investment in Summit Therapeutics. Summit announced the deal through Business Wire on 28 September 2026, after the US market close. The money buys convertible preferred stock. It does not buy a licence to...
When the Model Is Confident and the Patient Is Not
It is 2:07 a.m. in the emergency department. The waiting room is thin. The hallway is not. A middle-aged man looks pale. His vitals sit in the green band. A clinical decision support tile on the chart says low risk with a high confidence score. His wife keeps saying...
China Out-Licensing Deals 2026: The Billion-Dollar Tracker
In the first half of 2026, China’s innovative drug licensing deals reached $106.3bn, according to VBInsight data published by VCBeat. That total covers inbound and outbound deals. That compares with $135.7bn for the whole of 2025 on the same provider’s count. This...
What EU PFAS and Microplastics Rules Mean for Cosmetics Formulators
Cosmetics regulation rarely makes it onto the radar of pharma, biotech, or medical device professionals. It probably should, at least for the next few years. The European Union is in the middle of building two overlapping restriction regimes, one for PFAS and one for...
Small Cell Lung Cancer Treatment Filing Pulled Ahead of FDA Decision
Daiichi Sankyo and Merck have withdrawn a United States application for ifinatamab deruxtecan. The move takes a prospective small cell lung cancer treatment out of the American regulatory queue. The companies announced the withdrawal by Business Wire at 4:30pm Eastern...
Overcoming the Delivery Barrier: Systemic Virotherapy and Metastatic Cancer
The oncology field has made remarkable progress over the past two decades in defining the molecular and immunological drivers of cancer. Modern targeted approaches and immunotherapies have transformed outcomes for many patients, particularly when treating primary or...
How AI Is Redefining the Modern Healthcare Consultation
Healthcare in the United States is facing a structural inflection point. Physician burnout remains high. Administrative burdens consume hours that should be spent with patients. Chronic disease rates continue to rise. At the same time, health systems are under...
I’m a Black Gestational Carrier. How People Calculate My Risk Is Wrong
Adding Black maternal-health statistics to data on gestational carriers and calling the sum mine doesn't make it so. The numbers don’t work that way. I’ve carried three pregnancies for other families. I’m also a Black woman. Put those facts beside two well-documented...
Disease Progression Slowing Holds on Function, Misses on Composite
uniQure released four-year results for its Huntington’s disease gene therapy on Tuesday 29 September 2026. The disease progression slowing measured on the composite clinical scale narrowed at 48 months. It missed statistical significance. A second measure, Total...
The Writing Got Cheap. The Checking Did Not
Last month I published a cost analysis with wrong numbers in it. Not rounded wrong. I had taken the wrong price list and the wrong tariff for cache writes, and when I recomputed, the headline figure moved. I issued a corrected version and stopped citing the first one....
The Financial Infrastructure Behind Healthcare Innovation
Healthcare is changing faster than I have ever seen it change, and the revenue cycle has to keep pace. We are talking about AI, new treatments, new technology, new specialties and entirely new ways of delivering care. All of that is exciting, and much of it has the...
Why Complement Therapeutic Research Requires More Than a Single Assay
Complement-targeted drug development requires more than measuring individual proteins. Integrating functional hemolysis assays, carefully selected serum or plasma samples, and multiplex biomarker analysis can provide a more reliable picture of complement activity,...
AstraZeneca Strategic Equity Investment Puts $2bn Into Summit Therapeutics
AstraZeneca has made a 2 billion US dollar strategic equity investment in Summit Therapeutics. Summit announced the deal through Business Wire on 28 September 2026, after the US market close. The money buys convertible preferred stock. It does not buy a licence to...
When the Model Is Confident and the Patient Is Not
It is 2:07 a.m. in the emergency department. The waiting room is thin. The hallway is not. A middle-aged man looks pale. His vitals sit in the green band. A clinical decision support tile on the chart says low risk with a high confidence score. His wife keeps saying...
China Out-Licensing Deals 2026: The Billion-Dollar Tracker
In the first half of 2026, China’s innovative drug licensing deals reached $106.3bn, according to VBInsight data published by VCBeat. That total covers inbound and outbound deals. That compares with $135.7bn for the whole of 2025 on the same provider’s count. This...
What EU PFAS and Microplastics Rules Mean for Cosmetics Formulators
Cosmetics regulation rarely makes it onto the radar of pharma, biotech, or medical device professionals. It probably should, at least for the next few years. The European Union is in the middle of building two overlapping restriction regimes, one for PFAS and one for...
Small Cell Lung Cancer Treatment Filing Pulled Ahead of FDA Decision
Daiichi Sankyo and Merck have withdrawn a United States application for ifinatamab deruxtecan. The move takes a prospective small cell lung cancer treatment out of the American regulatory queue. The companies announced the withdrawal by Business Wire at 4:30pm Eastern...
Overcoming the Delivery Barrier: Systemic Virotherapy and Metastatic Cancer
The oncology field has made remarkable progress over the past two decades in defining the molecular and immunological drivers of cancer. Modern targeted approaches and immunotherapies have transformed outcomes for many patients, particularly when treating primary or...
Featured Articles
Further News
Why Digital Therapeutics Struggle to Enter Clinical Workflows
The practical barriers between promising digital therapeutic research and routine care, from validation and safety reporting to staff adoption and patient experience. A digital therapeutic can produce encouraging research results, receive regulatory clearance and...
Weekly News Roundup | 28 September 2026
Life science news 28 September 2026: four US drug approvals, three UK developments and two global R&D deals. The FDA approved Atebrioz, the third treatment for fibrodysplasia ossificans progressiva, and AbbVie’s Parkinson’s drug Juvmo. The MHRA approved...
Multi-Cancer Early Detection Test Divides FDA Advisers
A United States advisory panel has recommended approval of a multi-cancer early detection blood test. The Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee met on 23 September 2026. It reviewed GRAIL’s Galleri test. The assay reads...
Merck Wnt Agonist Meets Diabetic Macular Oedema Treatment Goal
Merck said on 24 September 2026 that remigromig met the primary endpoint of the pivotal Phase 2b/3 BRUNELLO study. Merck is known as MSD outside the United States and Canada. It said no new diabetic macular oedema treatment mechanism had matched anti-VEGF therapy in...
Online Prescribing Is Moving Faster Than Regulation
Online prescribing has moved from being a relatively niche part of healthcare to an increasingly established route through which patients access treatment. That change brings clear benefits. Patients can seek treatment discreetly, access clinicians without travelling,...
Clinical Trials Roundup | 25 September 2026
The clinical trial results 25 September 2026 span Sjögren’s, urticaria, IgA nephropathy, obesity, cutaneous lupus and Alzheimer’s psychosis. Amgen’s dazodalibep met its primary endpoint in systemic Sjögren’s disease. Celldex’s barzolvolimab met its primary and all key...
Rethinking the Office: The Need for Healthier Buildings
For property owners, management companies, and business leaders, few sights are more unwelcome than an empty office building. Indoor air quality may be part of the answer to filling it. In the post-pandemic era, the home office has replaced the traditional workplace...
When Life Sciences Compliance Problems Are Really Operations Problems
When a life sciences organization struggles during a regulatory inspection or quality audit, the first reaction is fairly predictable: people point to evolving regulatory expectations, expanding documentation requirements, or the complexity of maintaining compliance...
Obesity Drug Access in the UK: NHS and Private Routes in 2026
Obesity drug access in the UK now runs along two tracks that rarely meet. One is a publicly funded NHS rollout of tirzepatide (Mounjaro), phased over as long as 12 years. The other is a private market that has grown far faster. A UCL survey estimates that about 1.6...
Transfusion Medicine in 2026: from Hemovigilance to Bedside Precision
Transfusion medicine plays a crucial role in modern healthcare by ensuring the availability of safe and compatible blood products for patients in need. Recognized globally as an essential medicine, blood remains the cornerstone of the healthcare workflow. Every few...
Surgical Site Infections Can Consume Up to 75 Staff Hours
Surgical site infections can consume up to 75 staff hours and displace three operations, research finds A single surgical site infection (SSI) can consume an estimated 45 to 75 additional hours of healthcare staff time and create downstream demands equivalent to the...
Amylin Analogues Explained: The Next Obesity Drug Battleground
Amylin analogues have become one of the most active areas of obesity drug development. Novo Nordisk, Eli Lilly, Roche, Pfizer, AbbVie and AstraZeneca all hold clinical programmes built on the hormone amylin. The most advanced obesity candidate in the class, Novo...
Further News
Want to Be Part of the Next Chapter in Life Sciences Media?
LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.
Don’t wait for the media to pick up your story. Be the media.
See More Articles
Want to Be Part of the Next Chapter in Life Sciences Media?
LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.